Trial
NCT04904302
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
—
Condition
Advanced Clear Cell Renal Cell Carcinoma
Intervention
Nivolumab
Why stopped
Withdrawal of funding from the supporter (Mirati Therapeutics)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-20